Biotech company Ablynx wins European Mediscience Award: http://tiny.cc/knen6
posted 1 month ago
FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.
Galapagos NV (Euronext: GLPG) announced today that its Annual General Shareholders’ Meeting (AGM) held on 27 April 2010 approved Dr. Ronald Brus’ appointment to the Board of Directors, as well as all other agenda items of the AGM. Furthermore, the Extraordinary General Shareholders’ Meeting (EGM) held immediately after the AGM approved the creation of a new Warrant Plan for the benefit of the Directors. In addition, the Board of Directors approved the creation of a new Warrant Plan for the benefit of employees and independent consultants of the Company. read more
Galapagos NV (Euronext: GLPG) announced today a €2.1 million capital increase arising from employee warrant exercises as well as recent share purchases by senior management. Furthermore, Galapagos announced the licensing of a compound for ophthalmic disease to Bausch & Lomb. read more
ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on innovative medicines for eye disease, vascular disease and cancer, today announces that it has raised € 0.6 million as the result of the exercise of warrants by a number of the Company’s employees. read more
